CDC Says Clade I Mpox Outbreak Originating In Central Africa; Risk Of Mpox Coming Into U.S. Is Low; No Cases Of Clade I Mpox Have Been Reported In The U.S. At This Time; Best Protection Against Mpox Is Two Doses Of Jynneos Vaccine If Eligible; Working With Other U.S. Government Agencies & Partners On Strategy For Vaccination In Democratic Republic Of Congo
Portfolio Pulse from Benzinga Newsdesk
The CDC reports a Clade I Mpox outbreak originating in Central Africa, with a low risk of it entering the U.S. No cases have been reported in the U.S. The best protection is the Jynneos vaccine. The CDC is collaborating with U.S. agencies and partners on vaccination strategies in the Democratic Republic of Congo.
August 29, 2024 | 6:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Emergent BioSolutions, the manufacturer of the Jynneos vaccine, may see increased demand due to the CDC's emphasis on vaccination as the best protection against the Clade I Mpox outbreak.
The CDC's recommendation of the Jynneos vaccine as the best protection against Mpox could lead to increased demand for the vaccine, positively impacting Emergent BioSolutions, the manufacturer.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80